Advertise on podcast: State of Medtech

The next generation of surgical robotics may be defined as much by economics and workflow as by clinical capability. In this episode, I sit down with Jeffery Alvarez, Chief Strategy Officer at Moon Surgical, to explore how Scalable Surgery, physical AI, and ASC innovation could change the way surgical care is delivered. Jeffery explains why the traditional approach of solving rising surgical demand by adding more operating rooms, surgeons, staff, and technology is becoming increasingly difficult. Instead, he argues that healthcare needs systems designed around predictability, efficiency, accessibility, and flexibility across different sites of care. That thesis is central to Moon Surgical’s Maestro platform. Jeffery describes Maestro as a physical AI platform with perception, local computing, intelligence, and physical action built into the system. We discuss its FDA-cleared Copilot functionality, automated visualization, intelligent setup, portability, and how these capabilities are designed to reduce variability around the surgical workflow. We also examine the economics of ambulatory surgery centers, where high-volume facilities may complete significantly more procedures per room while turning cases much faster than traditional academic centers. Jeffery shares Moon Surgical’s reported evidence showing lower staffing requirements, shorter average procedure times, and meaningfully greater predictability across hundreds of procedures. The conversation also covers marginal cost of productivity, outpatient reimbursement, AI ecosystems, network effects, surgical workflow design, category creation, and the discipline required to build a startup around the needs of a specific market. The deeper opportunity is not simply creating another surgical robot. It is designing technology that allows more patients to receive high-quality surgical care with fewer resources and greater operational predictability. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #surgicalrobotics #scalablesurgery #physicalai #medtechinnovation #moonsurgical

The future of surgery may be defined less by where the surgeon is located and more by how reliably expertise can reach the patient. In this episode, I sit down with Brian Miller, CEO of SOVATO, to explore the infrastructure, robotics, and AI required to make remote procedures a scalable model of healthcare delivery. Brian explains why successful remote care requires much more than connecting a robotic system to a network. Hospitals also need reliable performance, secure connectivity, intelligent bandwidth management, clinical protocols, workforce planning, reimbursement pathways, and operational systems that allow remote care to function consistently. We discuss how remote capabilities could change specialist coverage across large healthcare systems. Brian shares an example where a thirty-hospital network might eventually be supported by a much smaller centralized group of specialists rather than requiring individual coverage at every facility. The conversation also explores the possibility of centralized surgeon cockpits, where physicians could connect into procedures across multiple hospitals while maintaining the situational awareness required for safe patient care. Brian identifies robotic ultrasound, interventional radiology, urology, cancer surgery, stroke care, and mechanical thrombectomy as areas where remote capabilities could become particularly valuable. We also go deeper into AI-enabled surgical autonomy, deterministic cloud computing, surgical video data, outcome prediction, CMS reimbursement discussions, healthcare workforce shortages, and the growing influence patients may have on access to specialized care. Ultimately, remote care is about something larger than robotics. It is about building infrastructure that allows healthcare systems to project expertise across distance and give more patients access to the right care at the right time. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #remotesupport #surgicalrobotics #medtech #healthcareinnovation #medicalrobotics

In this episode, Jacob McLaughlin sits down with Omar Khateeb to explore how medical device professionals can turn field experience into broader business judgment, leadership capability, and long-term career leverage. Omar shares his journey from medical device sales and surgical robotics into marketing, Silicon Valley, entrepreneurship, and building MarketCraft around the concept of MedTech market engineering. The conversation examines why medical device sales can become an unusually valuable business education. Reps work directly with physicians, hospitals, clinical workflows, logistics, budgets, technology adoption, and customer behavior, which can create a strong foundation for future roles in leadership, marketing, commercialization, and entrepreneurship. Jacob and Omar discuss why professionals should invest in their own development before an organization formally asks them to lead. Learning management principles, understanding P&L decisions, attending industry conferences, studying deeply, building relationships, and taking ownership of complex work can all increase professional leverage. The conversation also moves into category creation, positioning, messaging, thought leadership, fundraising, early clinical traction, and go-to-market strategy for MedTech startups. Omar explains how beachhead markets and reference density can help companies establish credibility before expanding, while first-principles thinking can help leaders question requirements, simplify systems, automate intelligently, and scale more effectively. The broader message is clear: the strongest careers and companies are often built by people willing to think several steps ahead of their current position. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #surgicalrobotics #medtech #surgery #medicalrobotics #healthcareinnovation

In this episode, Omar Khateeb speaks with Sudhir Srivastava, MD, Founder, Chairman & CEO of SS Innovations International Inc., about the evolution of surgical robotics and a future where surgical expertise can increasingly move across geography instead of requiring patients to travel toward it. Dr. Srivastava shares how decades in cardiac surgery shaped his view of minimally invasive care and eventually led him to build SS Innovations around a patient-centered goal: expanding access to advanced robotic surgery while reducing the barriers created by cost and geography. The conversation explores the development of the SSi Mantra platform and SS Innovations’ work in telesurgery. Dr. Srivastava says the company has completed nearly 200 telesurgeries , including robotic cardiac cases, and describes procedures performed across distances of 10,000 and 20,000 kilometers. He also discusses performing cardiac surgery remotely from his home, completing 24 telesurgeries in 12 hours with a team of surgeons, and using telepresence to mentor clinicians thousands of kilometers away. The discussion expands into the infrastructure surrounding next-generation surgery, including connectivity, AI, machine learning, semi-automation, remote ultrasound and biopsy, mobile operating rooms, surgeon education, and robotic technologies designed for emergency and underserved environments. For surgeons, MedTech executives, investors, and healthcare leaders, the episode provides a deeper look at how surgical robotics could evolve from a sophisticated operating-room platform into a broader system for extending expertise, training clinicians, and democratizing access to advanced care. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #surgicalrobotics #medtech #surgery #medicalrobotics #healthcareinnovation

In this solo episode, Omar Khateeb introduces a market engineering framework for MedTech founders who want to create stronger investor demand, clinical adoption, strategic visibility, recruiting leverage, and internal alignment. The thesis begins with a simple observation: companies frequently approach investors, physicians, strategics, and talented executives only when they need something from them. Omar argues that stronger companies begin building those relationships much earlier by consistently making their progress visible and understandable. Using the physics of magnetism as an analogy, Omar explains how founder vision, clinical milestones, physician validation, employee advocacy, investor attention, PR, social media, and market positioning become more powerful when every signal points in the same direction. This changes fundraising because investors can follow the company long before a financing round begins. They can watch the technology mature, see respected people join, observe clinical progress, and recognize physician engagement before receiving an investment deck. The same principle can influence commercialization and clinical adoption. Early physician innovators can validate the technology publicly, while their participation becomes another credibility signal visible to investors, strategic partners, employees, and potential recruits. Omar also explores why founders should begin recruiting before a position becomes available. Strong executives can follow a compelling company journey over time and eventually approach an opportunity with familiarity, context, and belief already established. The episode ultimately reframes social media as an infrastructure for distributing evidence of progress. When that evidence compounds consistently over two or three years, MedTech companies can become increasingly magnetic to the capital, clinicians, talent, and strategic relationships required for growth. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #medtechinnovation #marketanalysis #medtechindustry #healthcareinnovation

In this episode, Omar Khateeb sits down with Jenny Barba and Jeff Chu, Co-Founders and Managing Partners at Features Capital, for a detailed discussion on early-stage MedTech venture capital, clinical adoption, commercialization, capital efficiency, and the signals investors look for before a company reaches first-in-human studies or meaningful revenue. Jenny brings a finance and venture perspective shaped by billions of dollars in MedTech transactions, while Jeff brings decades of experience across product development, commercialization, technology, and company building. Together, they explain how Features Capital evaluates companies through both the future financial opportunity and the immediate execution path required to reach it. Their investment approach begins with the team. Founder grit matters, but Jeff argues that conviction becomes far more valuable when it is paired with self-awareness, the ability to absorb feedback, and the discipline to make meaningful strategic adjustments before capital is wasted. Clinical trials become another critical part of the conversation. Patient enrollment, site performance, study complexity, endpoint selection, and patient retention can materially change both development timelines and capital requirements, making clinical strategy an important component of venture strategy. Jenny and Jeff also explain why fast followers can become compelling MedTech investments when earlier companies have already established portions of the regulatory and reimbursement roadmap. Strong differentiation combined with faster execution, better outcomes, and greater capital efficiency can create meaningful competitive advantages. The conversation also explores AI-enabled biosensors, implantable medical devices, neurostimulation, cardiovascular innovation, metabolic health, precision medicine, minimally invasive therapies, and the continued importance of M&A as an exit pathway in MedTech. For MedTech founders and investors, this episode provides a practical framework for thinking about the journey from early technical proof to clinical adoption, institutional capital, commercialization, and ultimately strategic value. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuria #medtech #medtechindustry #venturecapital #medicaldevices #healthcareinnovation

In this solo episode, Omar Khateeb takes a deeper look at Qualified Small Business Stock, Section 1202, and the potential impact of QSBS on MedTech venture economics. The discussion begins with one of the industry’s most persistent challenges: MedTech requires significant capital and long development timelines before a company reaches regulatory approval, reimbursement, manufacturing scale, commercial adoption, or an eventual exit. Omar explores whether QSBS could help improve the after-tax return profile of successful MedTech investments, potentially making the sector more attractive to venture investors and limited partners competing across multiple asset classes. The episode explains why the 2025 changes matter, including partial exclusions beginning earlier in the holding period, a higher gross-assets threshold for qualifying companies, and a larger headline exclusion limit. Omar also examines which MedTech business models may deserve closer review for QSBS treatment, particularly product-driven companies built around medical devices, implants, surgical robotics, diagnostic technologies, intellectual property, engineering, and clinical evidence. For founders, the episode highlights several structural considerations, including domestic C corporation status, newly issued shares, secondary transactions, gross assets, and the timing of financing decisions. For venture funds, the conversation moves into an even broader question: whether QSBS can become part of portfolio construction, underwriting, LP fundraising, and after-tax performance strategy. Omar also introduces Section 1045, which may provide a pathway for certain qualifying investors to reinvest proceeds from an earlier exit into another eligible company, potentially helping capital move from one successful MedTech investment into the next. The central thesis is that QSBS should be viewed as a potential capital formation mechanism rather than simply a tax strategy, because stronger after-tax outcomes can influence where investors choose to allocate capital. This episode is educational only and does not constitute tax, legal, accounting, or investment advice. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #medtechindustry #venturecapital #startupfunding #founder

In this episode, Omar Khateeb joins Aneta Sottil, Partner at Andera Partners, for an in-depth conversation about MedTech investing, AI, category creation, commercialization, strategic M&A, and the signals that make healthcare innovation attractive to experienced venture investors. Aneta explains how the MedTech investment standard has evolved. Early technical promise still matters, but investors increasingly want stronger human data, evidence of meaningful clinical benefit, economic viability, reimbursement clarity, commercial potential, and a credible pathway toward value creation and liquidity. For companies building entirely new categories, Aneta focuses on whether the technology can move from being an interesting innovation to becoming something physicians and healthcare systems consider essential. The product needs to improve the patient care pathway in a way that is both clinically significant and economically sustainable. The conversation also explores the relationship between AI and traditional MedTech. While patented devices, implants, delivery systems, and other physical technologies can offer strong defensibility, Aneta believes future winners will increasingly integrate AI into product development, analytics, data interpretation, and predictive capabilities. Omar and Aneta discuss the evolving strategic buyer landscape, renewed MedTech M&A activity, surgical robotics, BCI, neuromodulation, reimbursement pathways, and the role experienced investors can play beyond providing capital. Aneta shares examples involving microsurgical robotics, neuromodulation for asthma, wearable defibrillation, and BPH technologies, demonstrating how investment decisions connect clinical need with market structure, team quality, commercialization strategy, and patient impact. The conversation ultimately highlights a broader principle for founders: creating MedTech value requires alignment between the product, clinical evidence, commercial strategy, investors, and the long-term direction of the company. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston: https://www.campcuriae.com/ #medtech #medtechinnovation #venturecapital #medicaldevices #healthcareinnovation

Learn more about Showpad's VIP Event here and use this - https://eitf.showpad.com/utm_source=omar&utm_medium=email&utm_campaign=eitf_ny_oct8&utm_content=personal_invite In this episode, Omar Khateeb joins Gavin Leonard, CEO of MedTech Syndicates, and Steven Kaplan, Director of the American Urological Association Innovation Nexus, for an in-depth conversation about MedTech venture growth, clinician-led investing, commercialization, and the rapidly evolving urology innovation ecosystem. Steven shares how the AUA Innovation Nexus developed from an innovation initiative into a platform supporting companies across multiple stages of development. Roughly 60 companies that have presented through the ecosystem have collectively raised approximately $570 million, while the program continues connecting entrepreneurs with clinicians, investors, strategic companies, and commercialization expertise. Gavin explains why he believes clinicians deserve a larger role in early-stage MedTech investing. Their direct understanding of patient needs, clinical workflows, and treatment limitations can provide a form of validation that traditional financial diligence may not capture alone. The conversation examines how clinician conviction can influence broader capital formation, including one example where early physician participation was followed by venture investors, family offices, and high-net-worth individuals during a $4.2 million raise completed in 90 days. Omar, Gavin, and Steven also discuss what happens after a startup reaches regulatory approval, including the difficult work of commercialization, reimbursement, coding, physician adoption, market creation, strategic engagement, and scaling into clinical practice. The episode also explores emerging areas of urology innovation, including bladder cancer, fertility, incontinence, overactive bladder, remote diagnostics, personalized patient communication, and technologies designed to improve healthcare efficiency. The broader takeaway is that successful MedTech innovation increasingly requires more than capital or technology alone because clinical validation, ecosystem access, commercialization strategy, and experienced partners can determine whether innovation ultimately reaches patients. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #urologyawareness #medicaldevices #healthcareinnovation #medtechindustry

In this episode, Omar Khateeb joins Virginia Giddings, Vice President of Exploration at Edwards Lifesciences, for a detailed conversation about early-stage MedTech innovation, strategic partnerships, structural heart, patient need, and what established medical device companies look for before commercialization. Virginia describes Edwards Lifesciences’ exploration model, where technical and clinical experts build relationships with emerging companies early enough to influence evidence development, reimbursement planning, market strategy, and potential portfolio fit. For founders, one of the most important lessons is to begin with the patient rather than the technology. Virginia explains why a sophisticated device becomes far more compelling when the team can clearly define the unmet need, understand the patient population, and connect the innovation to a realistic path toward adoption. The conversation also explores why trust, humility, coachability, and candor become strategic assets during diligence. Edwards does not expect every development program to be perfect, but Virginia emphasizes that transparent relationships make it easier to work through technical, clinical, regulatory, and commercial challenges together. She also shares an example of a relationship that started in 2015, grew through multiple stages of investment, developed into a structured deal, and eventually contributed to a new implantable heart failure monitoring business at Edwards. Omar and Virginia also discuss TAVR, heart failure, diagnostics, reimbursement, patient routing, AI, digital technologies, commercialization, and access to therapy. The conversation offers a valuable look at how one of MedTech’s leading structural heart companies thinks about discovering innovation before the opportunity becomes obvious. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #medtechinnovation #medicaldevices #startupstrategy #healthcareinnovation

In this episode, Omar Khateeb joins David Hochman, Chairman & CEO of Orchestra BioMed, for a deep discussion on MedTech commercialization, cardiovascular innovation, strategic partnerships, reimbursement, and long-term value creation. Orchestra BioMed is pursuing a model inspired partly by biopharma, where smaller innovators can advance clinical programs while partnering with global strategics that provide manufacturing, regulatory, and commercial scale. Instead of relying entirely on acquisition as the endpoint, Orchestra uses licensing and royalty structures designed to maintain participation in future product economics. David explains how this strategy works through Orchestra’s partnership with Medtronic around AVM therapy, which aims to expand the therapeutic capability of dual-chamber pacemakers by addressing hypertension through device programming. The approach reflects a larger theme throughout the conversation: some of the most meaningful MedTech innovations may come from adding new capabilities to technologies and procedures that clinicians already understand. The episode also examines Orchestra’s potential royalty economics, including $500 to $1,600 per AVM-enabled pacemaker sold, as well as the operational leverage that could emerge as commercialization responsibilities shift toward Medtronic. David also discusses the Virtue Sirolimus AngioInfusion Balloon, its role in coronary intervention, and why sustainable intellectual property, strong margins, clinical differentiation, and strategic fit are central to Orchestra’s partnership model. The founder lesson is equally important. David argues that MedTech companies should think about reimbursement, pricing, hospital economics, physician incentives, and the eventual commercial pathway from the earliest stages of development. The conversation provides a detailed look at how strategic partnerships, capital efficiency, clinical execution, and reimbursement strategy can shape the path from medical innovation to commercial scale. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #medicaldevices #medtechinnovation #healthcareinnovation #cardiovascularhealth

In this episode of This Month in MedTech, Omar Khateeb joins Henry Peck, CBO at LSI , for a data-driven discussion on autonomous robotics, physical AI, MedTech M&A, closed-loop devices, metabolic health, and the emerging intelligence layer around healthcare data. The conversation starts with one of the month’s most important technology milestones: FDA authorization for autonomous blood draws. Vitestro’s progress shows how robotics may expand beyond highly specialized surgery into high-volume clinical workflows where labor shortages and access constraints create a strong economic case for automation. Henry places that opportunity inside a clinical laboratory services market of roughly $220 billion. Omar and Henry then examine how the structure of MedTech itself may be changing. With 13 key deals totaling about $4 billion, large strategic acquisitions continuing at the top of the market, and smaller public companies facing compressed multiples and the cost of remaining public, the middle of the industry may be entering a new phase of consolidation and strategic repositioning. They also explore autonomous stroke robotics, the expansion of physical AI, and the shift toward medical devices that can sense physiological signals and respond through closed-loop systems. This evolution could reshape not only therapy delivery, but also cybersecurity, infrastructure, evidence generation, and the broader ecosystems built around intelligent devices. The discussion then turns to Abbott and Google, where continuous glucose monitoring becomes part of a larger strategic race around metabolic data, AI health coaching, and consumer context. If glucose data, behavioral information, and longitudinal health context become increasingly connected, the most valuable competitive advantage may belong to the platform that understands the patient most deeply. The episode closes by looking ahead to LSI Europe in Barcelona and the investors, strategics, founders, and emerging companies shaping the next chapter of MedTech innovation. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #healthcareai #physicalai #medicalrobotics #medtechinnovation

In this episode, Omar Khateeb sits down with Eric S. Heinz, Founder & Managing Partner of Heinz Ventures, for a wide-ranging discussion on MedTech venture capital, strategic M&A, early-stage funding, and the operating experience required to evaluate complex medical technology companies. Eric’s journey spans engineering, product management, turnaround work, corporate development, strategic acquisition, and venture investing, giving him a full-cycle view of how MedTech companies are built and how strategic buyers ultimately assess their value. The discussion examines why early-stage MedTech remains structurally underfunded, especially between angel financing and institutional venture capital, and why founders often need more than capital during the period when product strategy, regulatory planning, business development, and commercialization pathways are still taking shape. Eric explains how Heinz Ventures approaches pre-seed and seed investing with an operator’s perspective, focusing on opportunities where technical complexity and regulation can create meaningful competitive barriers. His thesis includes underserved innovation ecosystems across the Midwest and Southeast, where strong university IP and established MedTech talent often exist without equivalent access to early-stage venture capital. The conversation also goes deeper into strategic M&A and the importance of understanding the likely buyer before the exit process begins. With 90% of venture-backed MedTech companies exiting through M&A, Eric argues that acquisition strategy should influence diligence, product development, business development, and capital allocation much earlier than many founders realize. Omar and Eric also discuss neurotechnology, diagnostic and therapeutic platforms, imaging, robotics, investor conviction, portfolio support, and why operator experience can become a significant advantage when evaluating risk in MedTech DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #medtech #medtechindustry #venturecapital #neurotechnology #medicaldevices

In this solo episode, Omar Khateeb takes a deeper look at the convergence of AI, MedTech, healthcare investing, physical AI, intelligent medical devices, and market adoption. The episode begins with an unusual market setup: healthcare has increasingly attracted capital when investors become nervous about AI and semiconductor valuations, yet the same sector could become one of the biggest beneficiaries if AI successfully creates durable economic value outside the data center. Omar argues that healthcare may be especially well positioned because it combines massive datasets, expensive workflows, clinical complexity, connected devices, and physical systems where better intelligence can produce meaningful patient and economic outcomes. The conversation then moves into physical AI, where medical devices evolve beyond passive tools and become intelligent systems capable of sensing, predicting, and eventually influencing physical outcomes. In surgery, cardiology, monitoring, imaging, and robotics, that shift could fundamentally change what the hardware itself is capable of doing. Omar also explores simulation and synthetic data, why specialized medical robots may matter more than humanoid designs, how installed medical devices could become information networks, and why incumbents may gain new strategic advantages from clinical data and distribution. The episode ultimately asks a more useful question for MedTech founders: does AI simply add a feature, or does intelligence fundamentally expand what the medical device can understand, predict, and accomplish? DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #healthcareai #medtech #physicalai #medicaldevices #healthcareinnovation

In this episode, David Niewolny, Sr. Director and Global Head of Business Development for Healthcare and Medical at NVIDIA, joins Omar Khateeb for an in-depth conversation about the future of AI-powered medical robotics, GPU simulation, and software-defined MedTech. David explains why the next major challenge in healthcare robotics is giving systems enough varied experience before they ever reach a patient. Different anatomies, device interactions, sensor noise, tissue properties, and rare edge cases make physical data collection difficult, while simulation can expose robotic systems to controlled variations repeatedly and at scale. The conversation explores NVIDIA’s open-source medical simulation strategy, the role of Isaac for Healthcare, and why reusable infrastructure could help companies move faster without rebuilding foundational simulation and compute capabilities independently. David also discusses how 8,192 robotic training environments running in parallel reduced one medical robotics reinforcement-learning workflow from approximately five hours to about two minutes, illustrating how GPU acceleration can fundamentally change the cadence of product development. Omar and David then broaden the discussion into software-defined medical devices, edge computing, AI applications, automation, venture investment, and the possibility that future MedTech companies could increasingly resemble enterprise software businesses built on top of intelligent hardware platforms. For anyone following medical robotics, surgical AI, MedTech innovation, healthcare infrastructure, or digital transformation, this episode provides a detailed look at how NVIDIA is helping build the foundation for a more intelligent generation of medical devices. DISCLAIMER This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions. Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis. SUBSCRIBE YouTube: https://www.youtube.com/@thestateofmedtech LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/ FOLLOW THE STATE OF MEDTECH LinkedIn: https://www.linkedin.com/company/thestateofmedtech/ Instagram: https://www.instagram.com/stateofmedtech/ TikTok: https://www.tiktok.com/@stateofmedtechpod X: https://x.com/stateofmedtech Facebook: https://www.facebook.com/stateofmedtech FOLLOW OMAR M. KHATEEB LinkedIn: https://www.linkedin.com/in/okhateeb/ Instagram: https://www.instagram.com/omar.m.khateeb/ TikTok: https://www.tiktok.com/@omar.m.khateeb X: https://x.com/OmarMKhateeb Facebook: https://www.facebook.com/OmarMKhateeb Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/ #nvidia #surgicalrobotics #medtech #healthcareai #medicalrobotics